Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide

Life Sciences

Volumn 85, Issue 9-10, 2009, Pages 351-356

  Reis, Gláucia Maria Lopes ^a   Pacheco, Daniela ^a   Perez, Andréa Castro ^a   Klein, André ^a   Ramos, Marina Abadia ^a   Duarte, Igor Dimitri Gama ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anandamide; Cannabinoids; l arginine NO cGMP pathway; Opioids; Peripheral antihyperalgesia

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ANANDAMIDE; ARGININE; CANNABINOID 1 RECEPTOR; CYCLIC GMP; N(G) NITROARGININE; NALOXONE; NITRIC OXIDE; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; HYPERALGESIA; MALE; NONHUMAN; PAIN THRESHOLD; RAT;

ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; MALE; NITRIC OXIDE; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

RATTUS;

EID: 69049084382     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.06.012     Document Type: Article

References (53)

1. Amarante L.H., and Duarte I.D.G. The Kappa-opioid (+/-)-bremazocine elicits peripheral antinociception by activation of the l-arginine/ nitric oxide/cyclicGMP pathway. European Journal of Pharmacology 454 1 (2002) 19-23
2. Azad S.C., Marsicano G., Eberlein I., Putzke J., Zieglgänsberger W., Spanagel R., and Lutz B. Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse. European Journal of Neuroscience 13 3 (2001) 561-568
3. Beltramo M., Bernardini N., Bertorelli R., Campanella M., Nicolussi E., Fredduzzi S., and Reggiani A. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. European Journal of Neuroscience 23 6 (2006) 1530-1538
4. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., Glass M., and Zimmer A. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. European Journal of Pharmacology 396 2-3 (2000) 141-149
5. Calignano A., La Rana G., Giuffrida A., and Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394 6690 (1998) 277-281
6. Cichewicz D.L., Martin Z.L., Smith F.L., and Welch S.P. Enhancement of μ opioid antinociception by oral Δ9-tetrahydrocannabinol: dose-response analysis and receptor identification. Journal of Pharmacology and Experimental Therapeutics 289 2 (1999) 859-867
7. Corchero J., Avila M.A., Fuentes J.A., and Manzanares J. Delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sciences 61 4 (1997) 39-43
8. Corchero J., Fuentes J.A., and Manzanares J. Delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. European Journal of Pharmacology 323 2-3 (1997) 193-195
9. Duarte I.D.G., and Ferreira S.H. L-NAME causes antinociception by stimulation of the arginine-NO-cGMP pathway. Mediators of Inflammation 9 1 (2000) 25-30
10. Duarte I.D.G., Lorenzetti B.B., and Ferreira S.H. Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. European Journal of Pharmacology 186 2-3 (1990) 289-293
11. Ferreira S.H., Duarte I.D.G., and Lorenzetti B.B. The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. European Journal of Pharmacology 201 1 (1991) 121-122
12. Fimiani C., Mattocks D., Cavani F., Salzet M., Deutsch D.G., Pryor S., Thomas V., Bilfinger T.V., and Stefano G.B. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cellular Signalling 11 3 (1999) 189-193
13. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., and Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1, 2, 4]oxadiazolo[4, 3-a]quinoxalin-1-one. Molecular Pharmacology 48 2 (1995) 184-188
14. Guindon J., and Beaulieu P. Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50 7 (2006) 814-823
15. Guindon J., De Léan A., and Beaulieu P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 121 1-2 (2006) 85-93
16. Handy R.L., and Moore P.K. Effects of selective inhibitors of neuronal nitric oxide synthase on carrageenan-induced mechanical and thermal hiperalgesia. Neuropharmacology 37 1 (1998) 37-43
17. Hohmann A.G., and Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92 4 (1999) 1171-1175
18. Hohmann A.G., and Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 90 3 (1999) 923-931
19. Ibrahim M., Porreca F., Lai J., Albrecht P., Rice F., Khodorova A., Davar G., Makriyannis A., Vanderah T., Mata H., and Malan T.P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proceedings of the National Academy of Sciences 102 8 (2005) 3093-3098
20. Kawabata A., Nishimura Y., and Takagi H. l-leucyl-l-arginine, naltrindole and d-arginine block antinociception elicited by l-arginine in mice with carragenan-induced hyperalgesia. British Journal of Pharmacology 107 1 (1992) 1096-1101
21. Kawabata A., Manabe S., and Manabe Y. Takagi H.Effect of topical administration of l-arginine on formalin-induced nociception in the mouse: a dual role of peripherally formed NO in pain modulation. British Journal of Pharmacology 112 2 (1994) 547-550
22. Lépicier P., Lagneux C., Sirois M.G., and Lamontagne D. Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts. Life Sciences 81 17-18 (2007) 1373-1380
23. Lynn A.B., and Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. Journal of Pharmacology Experimental and Therapeutics 268 3 (1994) 1612-1623
24. Mackie K. Cannabinoid receptors as therapeutic targets. Annual Review of Pharmacology and Toxicology 46 (2006) 101-122
25. Maegawa F.A., and Tonussi C.R. The l-arginine/nitric oxide/cyclic-GMP pathway apparently mediates the peripheral antihyperalgesic action of fentanyl in rats. Brazilian Journal of Medical and Biological Research 36 12 (2003) 1701-1707
26. Malan T.P., Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F., and Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93 3 (2001) 239-245
27. Matsuda L.A., Lolait S.J., Bowstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 6284 (1990) 561-564
28. Mombouli J.V., Schaeffer G., Holzmann S., Kostner G.M., and Graier W.F. Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. British Journal of Pharmacology 126 7 (1999) 1593-1600
29. Munro S., Thomas L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 6441 (1993) 61-65
30. Nackley A.G., Suplita II R.L., and Hohmann A.G. A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behaviour in a rat model of inflammation. Neuroscience 117 3 (2003) 659-670
31. Nelson R.S., and Eichinger M.R. Role of nitric oxide (NO) in pulmonary dysfunction associated with experimental cirrhosis. Respiratory Physiology 126 1 (2001) 65-74
32. Pacheco D.F., Reis G.M.L., Francischi J.N., Castro M.A.S., Perez A.C., and Duarte I.D.G. δ-Opioid receptor agonist SNC80 elicits peripheral antinociception via δ1 and δ2 receptors and activation of the l-arginine/nitric oxide/cyclic GMP pathway. Life Sciences 78 1 (2005) 54-60
33. Pertwee R.G. Cannabinoid receptors and pain. Progress in Neurobiology 63 5 (2001) 569-611
34. Randall O., and Selitto J. A method for measurement of analgesic activity on inflamed tissues. Archives Internationales de Pharmacodynamie et de Therapie 111 4 (1957) 409-419
35. Reche I., Fuentes J.A., and Ruiz-Gayo M. Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu-and kappa-opioid receptors. European Journal of Pharmacology 318 1 (1996) 11-16
36. Reche I., Fuentes J.A., and Ruiz-Gayo M. A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. European Journal of Pharmacology 301 1-3 (1996) 75-81
37. Rice A.S.C. Cannabinoids and pain. Current Opinion in Investigational Drugs 2 3 (2000) 399-414
38. Rice A., Farquhar-Smith W., and Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia ininflammation and neuropathy. Prostaglandins Leukotrienes and Essential Fatty Acids 66 2-3 (2002) 243-256
39. Richardson J.D. Cannabinoids modulate pain by multiple mechanisms of action. Journal of Pain 1 1 (2000) 2-14
40. Richardson D., Kilo S., and Hargreaves M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 1 (1998) 111-119
41. Romano M.R., and Lograno M.D. Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels. British Journal of Pharmacology 147 8 (2006) 917-925
42. Sawynok J. Topical and peripherally acting analgesics. Pharmacological Reviews 55 1 (2003) 1-20
43. Sousa A.M., and Prado W.A. The dual effect of a nitric oxide donor in nociception. Brain Research 897 1 (2001) 9-19
44. Spina E., Trovati A., Parolaro D., and Giagnoni G. A role of nitric oxide in WIN 55, 212-2 tolerance in mice. European Journal of Pharmacology 343 2-3 (1998) 157-163
45. 9-tetrahydrocannabinol in mice. Brain Research 667 1 (1994) 77-82
46. Valverde O., Noble F., Beslot F., Daugé V., Fournié-Zaluski M., and Roques B.P. Δ9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. European Journal of Neuroscience 13 9 (2001) 1816-1824
47. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., and Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 5746 (2005) 329-332
48. Viganò D., Rubino T., and Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacology, Biochemistry and Behavior 81 2 (2005) 360-368
49. Vivancos G.G., Parada C.A., and Ferreira S.H. Opposite nocicptive effects of arginine/NO/cGMP pathway stimulation in dermal and subcutaneous tissues. British Journal of Pharmacology 138 (2003) 1351-1357
50. Walker J.M., and Huang S.M. Cannabinoid analgesia. Pharmacology and Therapeutics 95 2 (2002) 127-135
51. Welch S.P. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N, N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174, 864 or naloxone in mice. Journal of Pharmacology and Experimental Therapeutics 265 2 (1993) 633-640
52. Wildhirt S.M., Suzuki H., Horstman D., Weismüller S., Dudek R.R., Akiyama K., and Reichart B. Selective modulation of inducible nitric oxide synthase isozyme in myocardial infarction. Circulation 96 5 (1997) 1616-1623
53. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., and Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America 96 10 (1999) 5780-5785